66 results about "Fatty acid synthesis" patented technology

The present invention relates to a method of treating a fatty acid synthesis related disease comprising administering to a patient in need thereof an effective amount of a PARP inhibitor or metabolite thereof to inhibit fatty acid synthesis, wherein the fatty acid synthesis related disease is obesity, diabetes, or cardiovascular disease. The present invention also relates to a method of treating a cancer in a subject comprising: (i) identifying a level of fatty acid in a sample from the subject, and (ii) administering an effective amount of a PARP inhibitor or metabolite thereof to inhibit fatty acid synthesis in the subject, wherein the administration is based on the level of fatty acid, thereby treating the cancer in the subject. The present invention further relates to a method of treating Her-2 related cancers by administering to a patient in need thereof an effective amount of a PARP inhibitor or metabolite thereof to inhibit fatty acid synthesis.

The present invention is directed to nucleic acid molecules and nucleic acid constructs, and other agents associated with fatty acid synthesis, particularly the ratios of saturated and unsaturated fats. Moreover, the present invention is directed to plants incorporating such agents where the plants exhibit altered ratios of saturated and unsaturated fats. In particular, the present invention is directed to plants incorporating such agents where the plants exhibit altered ratios of monounsaturated to polyunsaturated fatty acids.

The present invention is in the field of plant genetics and provides recombinant nucleic acid molecules, constructs, and other agents associated with the coordinate manipulation of multiple genes in the fatty acid synthesis pathway. In particular, the agents of the present invention are associated with the simultaneous enhanced expression of certain genes in the fatty acid synthesis pathway and suppressed expression of certain other genes in the same pathway. Also provided are plants incorporating such agents, and in particular plants incorporating such constructs where the plants exhibit altered seed oil compositions.

Methods of producing fatty acid esters, such as fatty acid ethyl esters, from microorganisms genetically engineered to alter the expression of genes involved in fatty acid synthesis and / or ethanol production, such that a microorganism is obtained that can produce an alcohol, a fatty acid and an ester synthase in the absence of exogenously added alcohols.

The presently disclosed subject matter relates to metabolic reprogramming agents that decrease glutamine metabolism, glycolysis, and fatty acid synthesis, pharmaceutical compositions comprising at least one, at least two, or at least three metabolic reprogramming agents, and the use of those agents and compositions for treating metabolic reprogramming disorders, such as immune disorders (e.g., autoimmune diseases), inflammatory diseases, and transplant rejection, pathologies due to CNS inflammation due to infection and not involving infection, and neurodegenerative disorders.

The invention relates to compounds with selective inhibitory activity against aldolase and a preparation method thereof, pharmaceutical compositions containing the compounds, and application of the compounds to preparation of drugs for inhibiting the synthesis of triglyceride and cholesterol, drugs for reducing the synthesis of fatty acid, drugs for preventing and / or treating obesity and type 2 diabetes, drugs for preventing and / or treating tumors, drugs for preventing and / or treating Parkinson's disease, drugs for preventing and / or treating Alzheimer's disease, or drugs for prolonging the life of mammals. The general structure of the compounds is as described in the specification.

The presently disclosed subject matter relates to metabolic reprogramming agents that decrease glutamine metabolism, glycolysis, and fatty acid synthesis, pharmaceutical compositions comprising at least one, at least two, or at least three metabolic reprogramming agents, and the use of those agents and compositions for treating metabolic reprogramming disorders, such as immune disorders (e.g., autoimmune diseases), inflammatory diseases, and transplant rejection, pathologies due to CNS inflammation due to infection and not involving infection, and neurodegenerative disorders.

Recombinant nucleic acids and vector constructs encoding acyltransferases and variant thioesterases, and the acyltransferases and variant thioesterases encoded by the nucleic acids are provided. The acyltransferases and variant thioesterases are useful in fatty acid synthesis and triacylglycerol production. Host cells that express the recombinant nucleic acids as well as methods of cultivating thehost cells, methods of producing oils from the host cells are provided. The recombinant host cells and the oils produced therefrom have altered fatty acid profiles and / or triacylglycerols with altered regiospecificity.

The invention discloses weight-reducing health protection tea which is prepared from the following materials in parts by weight: 20-40 parts of semen cassiae, 20-40 parts of lotus leaf, 10-30 parts of ginseng and 10-30 parts of camellia chrysantha. The tea is rich in various effective weight-reducing health protection substances including tea polyphenol, total flavonoids, nuciferine, ginsenoside, vitamin, amino acid and trace elements, can convert redundant fat of the human body through manners of promoting lipolysis, inhibiting fatty acid synthesis, regulating substance metabolism and relaxing bowels, and can recover the energy metabolism of the human body, thus achieving the expected purpose of healthy weight reducing. Furthermore, the tea also has good health protection effect, can regulate the central nervous system of the human, strengthen the heart and resist fatigue, can achieve good qi-blood circulation of the body, and has good treatment effect on multiple diseases of the nervous system, the cardiovascular system, the endocrine system and the reproductive system.

The present invention provides for a genetically modified yeast host cell capable of producing one or more fatty acids, or fatty acid-derived compounds, or a mixture thereof, comprising: (a) increased expression of acetyl-CoA carboxylase (such as ACC1), (b) increased expression of one or more fatty acid synthases (such as FAS1 and FAS2), and (c) optionally reduced expression of one or more enzymes involved in or in the β-oxidation pathway (such as peroxisomal transporters PXA1 and PXA2, and β-oxidation enzymes POX1, POX2, and POX3).

The invention provides a culture method for increasing the grease content of saccharomyces cerevisiae by maintaining an ultralow-concentration organic carbon source and application of the culture method and belongs to the technical field of biology. Research finds that in the fermentation culture process of saccharomyces cerevisiae, the concentration of an organic carbon source in a fermentation culture solution is continuously maintained at an ultra-low level by controlling the supplementing amount of the organic carbon source, and in the state, activity of enzymes related to ethanol synthesis in saccharomyces cerevisiae cells is greatly reduced due to lack of an acting substrate, so activity of the enzymes related to ethanol synthesis in saccharomyces cerevisiae cells is improved. However, activity of enzymes related to fatty acid synthesis is not obviously influenced, so the flow direction of an organic carbon source deviates to fatty acid synthesis, and finally, a large amount of grease in saccharomyces cerevisiae cells is accumulated. The method is advantaged in that raw materials are low in cost, the culture method is simple and easy to implement, industrial production and application of the method are facilitated, and therefore the method has good actual production and application value.

The invention relates to methods for producing lipids such as fatty acid products in recombinant host cells engineered to express a non-native gene encoding a dehydrogenase. The recombinant microorganisms are able to proliferate at a higher rate as compared with microorganisms that do not express a non-native dehydrogenase gene, and cultures of microorganisms that are engineered for lipid production and that express a non-native dehydrogenase produce more lipid than cultures of control microorganisms that do not include a non-native dehydrogenase gene.

The invention relates to application of ssl2084 gene in synthesis of medium and long chain fatty acids. The ssl2084 is a protein capable of promoting synthesis of the medium and long chain fatty acidsin synechocystis, and has an amino acid sequence shown as SEQ ID NO. 2. The invention further relates to application of the ssl2084 gene in synthesis of medium and long chain saturated fatty acids ofthe synechocystis. For the first time, the invention discloses an important role of the ssl2084 gene of the synechocystis sp. PCC 6803 in synthesis of the medium and long chain saturated fatty acidsat low temperature. By increasing expression of the ssl2084 gene in the synechocystis sp. PCC 6803 by utilizing an overexpression method, contents of C12:0, C16:0 and C18:0 in mutant strains are significantly increased; and moreover, the contents of the C12:0, the C16:0 and the C18:0 in the mutant strains are further increased after low-temperature treatment, so that the recognition that it is easy to synthesize unsaturated fatty acids at low temperature in the field is changed.